CHENGDU KANGHUA BIOLOGICAL

Chengdu Kanghua Biological Q3 2026: Strong Profit Growth, mRNA Pipeline Expansion & Market Resilience

Chengdu Kanghua Biological Q3 2026 results show 15% profit growth, strong cash flow, and mRNA vaccine expansion—solid performance and future‑ready innovation for investors.

CHENGDU KANGHUA BIOLOGICAL
China
AI generated

Jake Connors

22/10/2026, 13:01

4 minutes to read

Chengdu Kanghua Biotech: Rising Earnings, Strong Cash Flow & Strategic Partnerships Power Up Next‑Gen Pharma

Chengdu Kanghua Biological shifts into high‑growth biopharma mode, combining solid earnings, strategic vaccine R&D, and strong liquidity for investors.

CHENGDU KANGHUA BIOLOGICAL
China
AI generated

Vanessa Liu

21/10/2026, 14:00

4 minutes to read